AMRN

DUBLIN and BRIDGEWATER, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report third quarter 2026 financial results and conduct a conference call on Wednesday, October 28, 2026. The Company will issue a press release detailing its third quarter 2026 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET. Information on how to participate is as follows. Access to the live call: Via telephone: Dial in within the United States: 888-506-0062 International dial in: 973-528-0011 Access Code: 314562 Via online: A webcast of the call will be available on the Investor Relations section of the Company's website at www.amarincorp.com. Access to the replay: Via telephone: Dial in within the United States: 877-481-4010 International dial in: 919-882-2331 Replay Code:54490 Via online: A replay of the webcast will be accessible through the Investor Relations section of the Company's website at www.amarincorp.com, beginning shortly after the end of the live call and available until 4/28/27. About Amarin At the Heart of Amarin Corporation is a singular focus on advancing cardiovascular disease prevention worldwide. Our flagship oral prescription therapy, VASCEPA® (icosapent ethyl or IPE), is the U.S. market leader across all available IPE products and has been prescribed more than 31 million times globally. Through our independent U.S. commercial operations and global commercial partnerships, Amarin supports access to VASCEPA/VAZKEPA® across nearly 100 markets worldwide. For more information, visit www.amarincorp.com and follow Amarin on LinkedIn, X, Facebook. To be added to the Company's email list and receive news directly, please visit https://investors.amarincorp.com/email-alerts. Availability of Other Information About Amarin Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (http://www.amarincorp.com/investor-relations), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin's investor relations website and may include social media channels. The contents of Amarin's website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. Amarin Contact Information Media Inquiries: Amarin Corporation plc [email protected] Investor Inquiries: Devin Sullivan & Conor Rodriguez The Equity Group on Behalf of Amarin [email protected] or [email protected] [email protected]

Bristol Myers Squibb BMY announced mixed phase III results for admilparant, its investigational treatment for idiopathic pulmonary fibrosis (IPF). The company also reported positive results from the phase III ACTION-1 trial evaluating RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). While RYZ101 met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS), admilparant met its primary endpoint only at the lower of the two doses tested. Consequently, the stock declined following the announcements despite the positive cancer trial results, reflecting investor concerns about admilparant's inconsistent dose response. While BMY stock opened higher, it reversed course and ended trading down 2.6% on Oct. 12. Shares of Bristol Myers have gained 6.8% year to date compared with the industry's growth of 2.6%. Image Source: Zacks Investment Research Admilparant is an investigational oral lysophosphatidic acid receptor 1 (LPA1) antagonist, which is being evaluated in adults with IPF. The phase III ALOFT-IPF trial evaluated admilparant at 60-mg and 120-mg doses, administered twice daily for at least 52 weeks, against placebo. Top-line results from the study showed that it met its primary endpoint at the 60-mg dose, with admilparant demonstrating a statistically significant improvement versus placebo in the absolute change in forced vital capacity (FVC) from baseline at week 52. FVC is an important measure of lung function, and slowing its decline is a key treatment objective in patients with IPF. The 120-mg dose slowed the decline in FVC but failed to achieve statistical significance. The mixed results across the two doses have likely disappointed investors, particularly given the positive efficacy signals reported in earlier-stage studies. In a global phase II trial, treatment with admilparant 60 mg twice daily for 26 weeks reduced the rate of lung function decline by 62% versus placebo in patients with IPF and a 69% reduction in patients with progressive pulmonary fibrosis (PPF). Although the phase III results support the drug's potential, the failure of the higher dose to meet statistical significance introduces some uncertainty regarding the consistency of its efficacy. The safety findings were encouraging. Admilparant demonstrated a well-tolerated safety profile at both doses, with low rates of discontinuation due to adverse events that were similar to placebo. IPF is characterized by irreversible scarring of lung tissue and a progressive decline in lung function. BMY will conduct a comprehensive evaluation of the ALOFT-IPF data and engage with health authorities to support planned regulatory submissions. The company expects top-line results from the fully enrolled phase III ALOFT-PPF trial in early 2027. The outcome will be key to determining whether admilparant can demonstrate broader efficacy across pulmonary fibrosis populations. In a separate announcement, BMY reported positive top-line results from the planned interim analysis of the phase III ACTION-1 study evaluating RYZ101 in patients with somatostatin receptor-positive GEP-NETs whose disease had progressed following treatment with Lu177-based therapy. The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in PFS, as assessed by blinded independent central review, compared with investigator's choice of standard of care. The comparator treatments included high-dose or high-frequency long-acting somatostatin analogues, everolimus or sunitinib. Safety results were consistent with the known safety profile of RYZ101. RYZ101 is an investigational targeted radiopharmaceutical therapy comprising DOTATATE linked to actinium-225, a potent alpha-emitting radioisotope. The positive ACTION-1 results mark a milestone for BMY's radiopharmaceutical portfolio. The study represents the first phase III trial to report results for an alpha-isotope-based targeted radiopharmaceutical therapy in any indication. The findings could support RYZ101's development as a potential treatment for patients with advanced GEP-NETs who have progressed following a Lu177-based therapy. The FDA granted RYZ101 Orphan Drug Designation for GEP-NETs in August 2026. Patients enrolled in the trial will continue to be followed for overall survival. BMY is undergoing a meaningful shift in its revenue mix, with its growth portfolio taking on a larger role and increasingly offsetting the pressure from mature products facing generic competition. Bristol Myers Squibb Company price-consensus-eps-surprise-chart | Bristol Myers Squibb Company Quote The company is actively reshaping its portfolio through new approvals, label expansions and pipeline development. The recent pipeline progress has been impressive as well. The FDA granted accelerated approval to iberdomide, in combination with daratumumab and hyaluronidase-fihj and dexamethasone under the brand name Zenbexus, for adults with multiple myeloma who have received at least one prior line of therapy. Zenbexus is the first FDA-approved cereblon E3 ligase modulator, adding a novel protein-degradation approach to BMY's oncology portfolio. The latest clinical updates provide a mixed picture of its pipeline progress. RYZ101's success in the phase III ACTION-1 study strengthens the company's radiopharmaceutical prospects. However, admilparant's mixed dose-level results in the phase III ALOFT-IPF trial introduce uncertainty, despite the statistically significant benefit demonstrated at the 60-mg dose and the favorable safety profile at both doses. Meanwhile, shares of Contineum Therapeutics CTNM plunged 36% following BMY's announcement. BMY's IPF study results create uncertainty for CTNM's investigational candidate PIPE-79 for IPF. Contineum is evaluating PIPE-791 in a phase II study. BMY currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the pharma/biotech sector are Amarin AMRN and Corcept Therapeutics CORT, currently sporting a Zacks Rank #1 (Strong Buy) each. You can see the complete list of today's Zacks #1 Rank stocks here. Over the past 60 days, loss per share estimates for Amarin have narrowed from 65 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 51 cents to 50 cents. Amarin's earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 62.27%. Over the past 60 days, earnings per share estimates for Corcept Therapeutics have increased from $1.13 to $1.86 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $2.35 to $3.48. Corcept Therapeutics' earnings missed estimates in two of the trailing four quarters, beat in one and met in the other, with the average surprise being 240.74%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Amarin Corporation PLC (AMRN) : Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report Contineum Therapeutics, Inc. (CTNM) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

It has been about a month since the last earnings report for Tango Therapeutics, Inc. (TNGX). Shares have lost about 6.2% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Tango Therapeutics due for a breakout? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent catalysts for Tango Therapeutics, Inc. before we dive into how investors and analysts have reacted as of late. Tango incurred a loss of 37 cents per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of 31 cents, as higher operating expenses weighed on the result. The company had reported a loss of 35 cents per share in the year-ago quarter. Collaboration revenues were zero compared with $3.2 million a year earlier. In the absence of a marketed product, Tango has no recurring product revenues. The company instead reports collaboration revenues periodically, depending on the terms and progress of its collaboration arrangements. All remaining deferred revenues from upfront and research option-extension payments under the Gilead collaboration were recognized during 2025. This followed the truncation of the collaboration agreement, which concluded all research activities. Consequently, Tango recorded no collaboration revenues in the reported quarter. Research and development expenses increased 13% year over year to $37.2 million in the second quarter of 2026. The increase primarily reflected higher spending related to the advancement of the vopimetostat and TNG456 clinical programs. The rise was partly offset by lower spending resulting from Tango's portfolio prioritization efforts. General and administrative expenses almost doubled year over year to $22.6 million, mainly due to higher personnel-related costs, including share-based compensation. In the past month, investors have witnessed a downward trend in estimates revision. The consensus estimate has shifted -10.16% due to these changes. Currently, Tango Therapeutics has a poor Growth Score of F, a grade with the same score on the momentum front. Following the exact same course, the stock has a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy. Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Tango Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Tango Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Amarin (AMRN), a stock from the same industry, has gained 2.4%. The company reported its results for the quarter ended June 2026 more than a month ago. Amarin reported revenues of $42.21 million in the last reported quarter, representing a year-over-year change of -42%. EPS of $0.04 for the same period compares with -$0.03 a year ago. Amarin is expected to post a loss of $0.15 per share for the current quarter, representing a year-over-year change of -1600%. Over the last 30 days, the Zacks Consensus Estimate has changed +15.2%. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #2 (Buy) for Amarin. Also, the stock has a VGM Score of B. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tango Therapeutics, Inc. (TNGX) : Free Stock Analysis Report Amarin Corporation PLC (AMRN) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Tango Therapeutics TNGX incurred a loss of 37 cents per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of 31 cents. The company had reported a loss of 35 cents per share in the year-ago quarter. Collaboration revenues were zero compared with $3.2 million a year earlier. Tango shares were down 4.8% on Tuesday, likely due to investor disappointment over the earnings miss. Higher operating expenses weighed on the result. In the absence of a marketed product, Tango has no regular source of income. The company instead reports collaboration revenues periodically, depending on the terms and progress of its collaboration arrangements. All remaining deferred revenues from upfront and research option-extension payments under the Gilead collaboration were recognized during 2025. This followed the truncation of the collaboration agreement, which concluded all research activities. Consequently, Tango recorded no collaboration revenues in the reported quarter. Research and development expenses increased 13% year over year to $37.2 million in the second quarter of 2026. The increase primarily reflected higher spending related to the advancement of the vopimetostat and TNG456 clinical programs. The rise was partly offset by lower spending resulting from Tango's portfolio prioritization efforts. Year to date, TNGX stock has skyrocketed 197.3% compared with the industry’s 5.5% growth. Image Source: Zacks Investment Research General and administrative expenses almost doubled year over year to $22.6 million, mainly due to higher personnel-related costs, including share-based compensation. Vopimetostat is Tango's lead pipeline candidate and an MTAP-selective, once-daily PRMT5 inhibitor. In June, the company reported initial data from a phase I/II study evaluating vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitors daraxonrasib or zoldonrasib in patients with MTAP-deleted, RAS-mutant pancreatic cancer. Per the data readout, the combo achieved a 92% objective response rate and 90% six-month progression-free survival rate in this patient population, with a generally well-tolerated safety profile. The findings strengthened Tango's focus on advancing vopimetostat in pancreatic cancer. The company is working internally and has begun discussions with regulators and Revolution Medicines toward developing a registrational plan and path forward for vopimetostat plus daraxonrasib in MTAP-deleted pancreatic cancer. The design of this impending phase III study of the combo drug in front-line pancreatic cancer is expected to be finalized later in 2026. Beyond pancreatic cancer, Tango expects to disclose phase I/II vopimetostat lung cancer monotherapy data later in 2026. The update is expected to provide another clinical readout for the company's lead PRMT5 program in a different tumor setting. The company also plans to release initial data from an early- to mid-stage study of TNG456 for glioblastoma and other cancers and to initiate a phase I/II study of vopimetostat in combination with Erasca's ERAS-0015 in patients with MTAP-deleted RAS-mutant cancers later in 2026, thereby extending development across its broader oncology pipeline. Tango Therapeutics, Inc. price-consensus-eps-surprise-chart | Tango Therapeutics, Inc. Quote Tango currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Amarin AMRN, Repligen RGEN and Liquidia Corporation LQDA, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. The estimate for Amarin’s 2026 loss per share is currently pegged at 65 cents, while that for 2027 is currently pegged at 51 cents. AMRN shares have gained 2.2% year to date. Amarin’s earnings beat estimates in three of the trailing four quarters and missed on the remaining occasion, delivering an average surprise of 62.27%. Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares have declined 3.2% year to date. Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%. Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 158.4% year to date. Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tango Therapeutics, Inc. (TNGX) : Free Stock Analysis Report Repligen Corporation (RGEN) : Free Stock Analysis Report Amarin Corporation PLC (AMRN) : Free Stock Analysis Report Liquidia Corporation (LQDA) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Image source: The Motley Fool. Wednesday, July 29, 2026 at 2:00 p.m. ET President and Chief Executive Officer - Aaron Berg Executive VP, President of Research & Development and Chief Scientific Officer - Steven Ketchum Chief Financial Officer - Pete Fishman Investor Relations - Devin Sullivan Operator: Good morning, and welcome to Amarin Corporation's conference call to discuss its Second Quarter 2026 Financial Results. Please note that this conference is being recorded. I would now like to turn the conference over to Devin Sullivan, Investor Relations for Amarin. Devin Sullivan Thank you for your time and attention this morning as we discuss Amarin's 2026 second quarter financial results. On today's call are Aaron Berg, President and Chief Executive Officer; Steve Ketchum, President, Research & Development and Chief Scientific Officer; and Pete Fishman, Chief Financial Officer Other members of the senior management team will be available as needed during the Q&A session following the prepared remarks. Aaron will provide a state-of-the-company update. Steve will review recent medical and regulatory activities, and Pete will discuss the numbers. Before we begin, I'd like to remind everyone that today's press release and related Quarterly Report on Form 10-Q will be available on the Investor Relations section of the company's website, www.amarincorp.com, as well as a replay of this call shortly after its completion. Please be aware that during this call, we may make certain statements related to our business that are deemed forward-looking statements under federal securities laws. These statements are not guarantees of future performance, but rather are subject to a variety of risks and uncertainties. Our actual results could differ materially from expectations reflected in any forward-looking statements. Additionally, we assume no obligation to update these statements as circumstances change. For a discussion of the material risks and important factors that could affect our actual results, please refer to our SEC filings, which are available either on our company website or the Securities and Exchange Commission's EDGAR system. With that said, I'd now like to turn the call over to Amarin's President and CEO, Aaron Berg. Aaron, please go ahead. Aaron Berg: Thanks, Devin, and thank you all for joining us today. Q2 2026 marked an inflection point for Amarin, highlighting the 1-year anniversary of our dual commercial strategy that combines continued execution of our U.S. business with a fully partnered international commercial platform. The successful implementation of these actions has resulted in a scalable business model while defining a clear path towards sustainable growth and profitability. We're seeing a promising early-stage international sales trajectory in a number of markets where there remains significant unmet need and long-term potential for VAZKEPA while preserving a leading U.S. presence for VASCEPA, supported by a financial foundation that includes a growing cash position and no debt. Our restructuring activities are now complete, resulting in a significantly lower cost base. This refined organizational structure and expense framework will enhance our ability to efficiently execute our long-term growth strategy. As you may have noticed in our press release, we're now able to provide an outlook for certain key metrics for full-year 2026, reflecting the clarity afforded by our new operating model and the strong partnerships that make up its foundation. This underscores how far the business has progressed in the past year while validating our global go-to-market initiatives and reinforcing the continued outstanding execution of our talented, committed team. As of June 30, 2026, VASCEPA was commercially available in 22 countries via both our fully partnered international commercial strategy and company-managed U.S. presence. Our accelerating international growth is being driven primarily by our exclusive license and supply agreement with Recordati, which covers 59 countries across Europe, as well as our 6 other commercial partnerships in the rest of the world that cover regions, including Canada, China, Israel, the Middle East, Asia, Australia and New Zealand. Across this combined global partner network, in-market demand for VASCEPA rose by 59% in cumulative year-over-year volume as of June 30 compared to the same period last year. As of the end of Q2, VAZKEPA is commercialized in 11 countries in Europe, including a recent launch in Romania, and Recordati continues to invest meaningfully with pricing, reimbursement, market access and adoption advancing in numerous additional countries across the licensed territory. Under Recordati's leadership, VAZKEPA is in an early but promising stage of commercialization in Europe's large cardiovascular market, where the disease affects an estimated 62 million people and carries an annual economic burden of approximately EUR 282 billion across the European Union. In-market demand in Europe for VAZKEPA under the Recordati partnership rose by 69% in Q2 2026 from Q2 2025. Spain and the U.K., though early, are leading commercial adoption, providing a strong foundation for future growth as pricing, reimbursement, and commercialization efforts continue across the broader territory. In Italy, where Recordati has one of the country's most established pharmaceutical commercial organizations, VAZKEPA launched with significant commercial support and has demonstrated strong early uptake. VAZKEPA is positioned by Recordati as a priority brand in its cardiovascular portfolio, backed by an expanded cardiovascular commercial infrastructure across Europe, including dedicated field representatives, medical science liaisons and marketing investment. In its 2025 annual report, Recordati referred to VAZKEPA as a best-in-class treatment option that complements its existing cardiovascular portfolio, is supported by a robust clinical data package and makes a meaningful impact for cardiovascular patients with residual cardiovascular risk. While driving utilization in launch markets, Recordati is actively progressing pricing, reimbursement, and market access across additional territories, building a meaningful base for long-term royalty and milestone growth as additional countries come online. While very early, the commercial performance since the June 2025 licensing transaction is encouraging in that Recordati's established cardiovascular infrastructure, broader geographic footprint, and tremendous execution have unlocked substantially greater value from VAZKEPA than would have otherwise been possible had Amarin continued VAZKEPA commercialization throughout Europe alone. The commercial momentum generated by Recordati thus far materially exceeds historical European growth rates achieved by Amarin prior to the licensing transaction. As a reminder, European markets each follow their own regulatory process for pricing, reimbursement and market access, so commercial launches can progress at different speeds and under varying requirements across countries despite an overarching EU framework. In the U.S., our core business continues to serve as a highly efficient tax-generating base with VASCEPA retaining a leading position in the icosapent ethyl market despite ongoing generic pressure. We continue to expect to maintain our exclusivity with key payers through the end of 2026. The overall U.S. IPE market, based on third-party data, rose by 3% in Q2 2026 compared to Q2 2025. VASCEPA's share of the market rose to 48% as of June 30, 2026, up from 43% in the same period last year. Despite continued pricing pressure, VASCEPA branded prescriptions increased 14% year-over-year in the second quarter of 2026, reflecting continued commercial execution in a competitive market. We expect U.S. volumes to remain stable through the end of 2026. Outside of Europe and the U.S., we continue to support our partners in advancing regulatory submissions in various other countries across Asia. We recently received approvals in Singapore and South Korea and look forward to the launches in these territories in 2027. As our international footprint continues to expand, the work of our medical affairs, regulatory, and R&D teams becomes increasingly important. Beyond supporting Amarin's own scientific objectives, these teams provide critical expertise to our commercialization partners around the world to contribute to our joint success, helping them navigate local regulatory requirements, continuing to contribute to an already robust library of scientific evidence supporting the benefits and unique attributes of icosapentethyl, engaging with key scientific leaders, supporting reimbursement discussions, and preparing for successful product launches. Through scientific exchange, congress participation, publication support, medical education initiatives and ongoing regulatory collaboration, these teams help ensure that our partners have access to the latest data and insights supporting VASCEPA as they work to improve access for patients in their respective markets. To provide additional perspective on the scientific, medical and regulatory activities supporting our global growth strategy, I'll now turn the call over to Steve Ketchum. Steve? Steven Ketchum Executive VP, President of Research & Development and Chief Scientific Officer Thank you, Aaron. Supporting our global commercialization strategy is an experienced medical affairs, regulatory, technical operations, and R&D organization that works closely with our partners throughout the product life cycle, from regulatory submissions and scientific exchange to market access and commercial launch. Together, these teams help advance the science behind VASCEPA and VAZKEPA while enabling successful regional commercialization across our global partner network. Our commitment extends well beyond supplying product. We believe sustained scientific leadership is one of the most important ways we create value for patients, health care providers and our partners. More than 7 years after the landmark REDUCE-IT results and more than 6 years after the U.S. approval of VASCEPA for cardiovascular risk reduction, we continue to invest in meaningful scientific research that expands our understanding of cardiovascular risk and reinforces the role of high-dose VASCEPA in contemporary clinical practice. Beyond generating new evidence, our teams work closely with partners through publication initiatives, scientific congresses, key opinion leader engagement, launch planning, regulatory support and medical education, helping ensure they are equipped with the latest evidence to support successful commercialization and expand patient access across global markets. That commitment is reflected in a steady cadence of scientific advancements, guideline recognition and partner-led educational initiatives that continue to strengthen the global evidence base for high-dose VASCEPA Icosapent ethyl. In May, we announced new data from a post-hoc analysis of the REDUCE-IT trial that was presented at the European Atherosclerosis Society, or EAS, Congress in Athens, Greece. The analysis conducted in the REDUCE-IT placebo arm found that among statin-treated patients with elevated triglycerides, risk-weighted apolipoprotein B, or apo B, more effectively identified patients who remained at increased residual cardiovascular risk compared with traditional lipid biomarkers. These recent findings add to the body of evidence that many high-risk patients continue to face substantial residual cardiovascular risk despite statin therapy and highlight the potential value of more refined lipid metrics to better identify patients who may benefit from evidence-based treatment. Prior findings from REDUCE-IT have shown that VASCEPA consistently reduced major adverse cardiovascular event risk across the spectrum of lipoprotein A levels, including in patients with elevated lipoprotein A, an increasingly recognized contributor to residual risk. These previously published findings suggest that any future benefits from emerging lipoprotein A-lowering therapies may be complementary to the established cardiovascular risk reduction demonstrated with VASCEPA. This growing body of evidence complements the continued recognition of high-dose icosapent ethyl and leading international treatment guidelines. Both the 2026 ACCAHA multi-society dyslipidemia guideline and the more recently released ACCAHA Multi-Society cardiovascular kidney metabolic syndrome guideline formally recommend high-dose icosapent ethyl for appropriate high-risk patients. Together with recommendations from more than 70 medical societies worldwide, these endorsements underscore the strength of the evidence supporting VASCEPA and reinforce its important role in addressing residual cardiovascular risk. Looking ahead, we remain committed to advancing the science that supports patients, clinicians and our commercialization partners. Early next month, we will support our Australian partner, CSL Seqirus, at the Cardiac Society of Australia and New Zealand, or CSANZ Annual Scientific Meeting in Sydney. As one of the region's premier cardiovascular congresses, CSANZ provides an important forum for scientific exchange and physician education. During the meeting, CSL Seqirus will sponsor a medical education session entitled Transforming Secondary Prevention after MI, Imaging Residual Risk and targeting what remains, featuring Professors Peter Psaltis and Adam Nelson, in addition to presenting many oral abstracts entitled Benefits of icosapent ethyl in patients with prior peripheral artery disease, REDUCE-IT-PAD. We are proud to support these efforts as part of our broader commitment to advancing cardiovascular science and helping our partners educate clinicians with the latest evidence. Later in August, we will also participate in the European Society of Cardiology Congress in Munich. As one of the world's largest cardiovascular meetings, bringing together more than 33,000 health care professionals from nearly 170 countries, ESC provides an important platform to share new scientific findings. We are pleased to have five scientific abstracts accepted, including multiple new REDUCE-IT analyses and mechanistic data that continue to deepen our understanding of the clinical benefits of high-dose VASCEPA. We also anticipate the release of the European cardiovascular kidney metabolic guideline during the ESC meeting, representing another important milestone for cardiovascular care and providing an additional opportunity to engage the global scientific and clinical community. Our continued investment in science reflects a simple belief. Strong clinical evidence drives better patient care while creating long-term commercial opportunity. Beyond supporting current commercialization efforts, we continue to evaluate cost-effective opportunities to further advance the science of icosapent ethyl and explore potential future life cycle management initiatives. While these efforts remain in the early stages and no development decisions have been made that are appropriate for public disclosure today, we believe disciplined scientific innovation remains an important component of long-term value creation. We will communicate developments when there are meaningful updates to share without setting unrealistic expectations. By continually expanding the evidence base and providing our partners with ongoing scientific, regulatory, technical, operational and medical expertise, we are helping accelerate global access to VASCEPA and VAZKEPA, support successful commercialization across international markets and ultimately improve cardiovascular outcomes for patients worldwide. With that overview of our scientific progress and partner support activities, I'll turn the call back to Aaron. Thanks, Steve. Before turning things over to Pete, I want to emphasize that the story we've altered is functioning as intended, with each chapter of execution adding momentum that supports the next phase of growth. We'll continue to advance our organic growth initiatives and execute with a high level of financial and operational discipline. Additionally, we continue to work closely with our exclusive financial adviser, Barclays, as we actively evaluate additional potential opportunities to enhance shareholder value. Our commitment to patient care remains the foundation of everything we do, shaping our strategy, guiding our decisions and directing our investments. With that, I'll now turn the call over to Pete to take us through the numbers. Peter Fishman: Thanks, Aaron. As Aaron mentioned, the benefits of our dual sales model and now completed restructuring plan are becoming increasingly clear with execution against three key priorities: advancing international growth through our partners, operating with a significantly lower cost base and continuing to strengthen cash generation. In summary, European product revenue increased from Q1 2026, and total operating expenses, excluding restructuring charges, materially declined from Q2 2025. We also generated positive cash flow for the third consecutive quarter and improved our cash position by $12 million from year-end 2025. Total net revenue in Q2 2026 was $42.2 million compared to $72.7 million in last year's second quarter, which included a $25 million upfront payment associated with the commencement of the Recordati transaction. Product revenue was $39.1 million compared to $46.6 million. By geography, U.S. product revenue declined to $32.2 million from $36.5 million in Q2 2025, driven by ongoing pricing pressure in the competitive generic market, partially offset by higher product volumes. Importantly, despite this pricing pressure, the U.S. business remains profitable and continues to generate cash. Second quarter product revenue in Europe was $5.4 million under our new partner model and consisted entirely of supply shipments to a record high. This compared to $6.6 million in the second quarter of 2025 under our previous sales model. Lower revenue despite the increased in-market demand of 69% reflected the transition to record high. Q2 2026 European revenue increased 11% from Q1 2026 and was up by 140% from Q4 2025. We're encouraged by this early momentum. Rest of World revenue in Q2 2026 was $1.4 million, down from $3.5 million in the prior year period, reflecting normal variances across multiple geographies as these respective markets continue to develop. Cost of goods sold in Q2 2026 rose 22% to $27.2 million from $22.4 million due to increased product volumes, primarily associated with regaining an exclusive PBM relationship in the U.S. beginning in Q3 2025. Lower operating expenses reflected the success of the now completed global restructuring, which we commenced in mid-2025. The decrease was in line with the previously announced approximately $70 million in annual cost savings and established a more efficient operating expense baseline. In Q2 2026, total operating expenses declined by 59% or $39.3 million to $27 million. Excluding the restructuring charge of $22.8 million in Q2 2025, total operating expenses decreased 38% from the prior year period. We incurred no material restructuring charges in Q2 2026. Selling, general and administrative expense for Q2 2026 was $22.2 million, a 43% decline from $38.7 million one year ago. R&D expenses were in line with our ongoing commitments and our partners' ongoing expansion into new markets. R&D reflects our commitment to global regulatory support and to the science underlying our global branded product. Our operating loss in the second quarter narrowed to $12 million from an operating loss of $16 million in last year's second quarter. Despite the increase in cost of goods for the quarter, we narrowed our operating loss by 25%. Turning to the balance sheet. We ended the quarter with cash and investments of $314.6 million, up from $303 million at year-end 2025, with no debt and working capital of $439 million. Importantly, we generated $7 million of positive cash flow from operations in the second quarter, our third consecutive quarter of positive cash flow, and we continue to expect positive cash flow for full year 2026. Given the stronger cash position and continued cash generation, I also wanted to briefly address our previously authorized share repurchase program. We recognize that many shareholders are eager for an update, and we appreciate your continued interest. As we have discussed previously, the U.K. High Court approval obtained in connection with the authorization remains in effect through Q2 2029. Since obtaining that approval in 2024, the business has evolved considerably. Today, we are operating from a stronger financial position with improved cash generation. We understand our responsibility to deploy capital in a way that benefits shareholders. Capital deployment can take a number of forms, and we will continue to evaluate our options carefully and provide updates if and when there are material developments. Disciplined inventory management remains a high operational priority and an important driver of cash flow and overall business health. As of June 30, 2026, inventory declined by $19.5 million from March 31, 2026, and by $31.8 million from December 31, 2025. This reflects our multiyear approach to purchasing API at the appropriate time, considering manufacturing lead times, supply continuity requirements, and evolving demand trends across our markets. This discipline allows us to support expected commercial demand while avoiding unnecessary working capital tied up in inventory. The business continues to strengthen, supported by key milestones achieved over the past year. Under our new operating model, we are operating with a leaner cost structure, working capital discipline, and greater financial flexibility to support our U.S. profitability and sustainable international growth through our partners. I now ask the operator to open the call to questions. Operator: Your first question for today is from Paul Choi with Goldman Sachs. Kyuwon Choi: Aaron, the first one is just on the reimbursement landscape in Europe. I appreciate that it's country by country. But in terms of the major markets, can you maybe give us an update on what still needs to be done in the various key geographies in Europe? And then my second question for Peter is just on cost of goods coming in a little bit higher than I think the Street had been modeling. Can you maybe just help us understand if this is the sustainable rate that you're expecting given volume growth that you're anticipating here on a go-forward basis? Aaron Berg: Paul, thanks for the question. Appreciate it, and thanks for joining us. Regarding Europe and reimbursement, as you noted, it's a different pace and different rate across all the countries. So where we've launched, or now Recordati is commercializing primarily in the U.K., Spain, Portugal, as well as now getting off the ground in Italy. The reimbursement is there, always looking for ways to improve regionally. But given the growth in end market demand, we're very pleased with where we are and how Recordati has made commercializing VASKEPA a priority. And they even noted the strong growth yesterday themselves in their earnings call. They're also evaluating a number of other countries. I mean ultimately, we'd like to see the ability to launch in France; that would be, of course, sometime in the future. But obviously, we have confidence in our partner to be able to do something there, but we just don't have an update at this time. As you know, it's a lengthy process there. They have partnered with us in 59 countries. They're exploring a number of countries that we as Amarin would never even have considered, and some of those are sizable markets. Hopefully, we'll see how that plays out, and we can get reimbursement in those countries and ultimately launch as well. So off the ground early. Back to Italy, that's a very big omega-3 market. It certainly is one that Recordati knows extremely well, a very established, competent cardiovascular organization. And they're off the ground strong, and the more they get regional reimbursement and favorable reimbursement there, we're excited about what they can do there. So overall, we're pleased with Europe. A lot of work to do, very early, 15-year partnership, as you know. And right now, we're extremely encouraged. Pete, do you want to touch on the COGS? Peter Fishman: Yes. Thanks, Aaron. So as you know, COGS is calculated using a weighted average cost of our inventory on hand, which is primarily driven by our API for the volumes sold in the quarter. When you look at the comparison from Q2 '26 to Q2 '25, the increase is due to regaining that PBM exclusive, which was effective in Q3 2025. So when you look at Q3 compared to Q2 in 2026, that material variance, and also when you look at Q3 '25 to Q3 '26, that material difference, you should start to see it level off. You're right that the primary driver is that increase in volume. But as we've talked about in the past, we've spent the last few years renegotiating the supply agreements that have enabled us to drive our inventory levels down to more appropriate levels, but it's also allowed us to manage the cost structure in our purchasing. Operator: Your next question is from Jessica Fye with JPMorgan. Unknown Analyst: This is Jose on for Jess. On the licensing revenues of $3.1 million in the second quarter, curious if you're seeing any revenues from Recordati starting to roll in this year? And if so, what should we expect Recordati revenues to ramp up in the second half and beyond? Aaron Berg: I'll comment on growth from an end market perspective, and then I'll have Pete talk about the revenue side of things. And as you know, we're not to give revenue guidance, but Pete will comment on that. Obviously, the more that they grow in market demand, the greater the acceleration in revenue growth as well. The end market demand has been tremendous at 69% for Recordati for Europe, and they just got started. So we're encouraged by what that will do. Obviously, the more we can help them, the more they invest in market demand, the more it will drive revenue. Pete, do you want to comment on the numbers on revenue specifically? Peter Fishman: Yes. On the licensing revenue, that also includes royalty revenue. And so there is a portion of that is made up from Recordati. There was $1.4 million in royalty revenue for the quarter, which is a growth from Q1. So as you're seeing that end market demand growth, you're also seeing product revenue growth of 11% from Q1 '26. So we are seeing that growth. We're encouraged by the continued momentum in the early stages from Recordati. But yes, when you look at the licensing revenue line of $3 million, there is a portion of that related to Recordati. Operator: We have reached the end of the question-and-answer session, and I will now turn the call over to Aaron for closing remarks. Aaron Berg: Thank you, operator. We continue to have strong confidence in our strategy. We've got optimism about the scale of the opportunities that lie ahead, long-term partnerships, and a lot of untapped potential worldwide. And certainly, we have a tremendous product that continues to provide that benefit. So we're executing extremely well. We've got enormous pride in our team, and the commitment and the progress that we're making with this new strategy, and we look forward to continuing to report those results to you. So thank you all for joining us today. I appreciate you taking the time and look forward to keeping you apprised of our progress. Have a good day. Operator: This concludes today's conference, and you may disconnect your lines at this time. Thank you for your participation. Before you buy stock in Amarin Plc, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amarin Plc wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $397,405!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,344,091!* Now, it’s worth noting Stock Advisor’s total average return is 953% — a market-crushing outperformance compared to 214% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of August 7, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Amarin (AMRN) Q2 2026 Earnings Call Transcript was originally published by The Motley Fool

Strong international demand growth and lower operating expenses supported improved profitability metrics as Amarin reaffirmed confidence in its global commercialization strategy. Amarin (NASDAQ:AMRN) reported strong international in-market demand growth, with partner network sales increasing 59% year over year despite lower reported revenue. The company completed its $70 million annual cost savings initiative, reducing operating expenses by 38% excluding restructuring charges. Cash increased to $314.6 million, and Amarin remained debt free while generating positive operating cash flow for a third consecutive quarter. VASCEPA strengthened its U.S. position, with market share rising to 48% and branded prescriptions increasing 14% year over year. Management expects cash to grow by approximately 10% by the end of 2026 and anticipates stable U.S. sales volumes throughout the year. Amarin (NASDAQ:AMRN) reported second-quarter 2026 total net revenue of $42.2 million, down 42% from the prior year. The decline primarily reflected the absence of the $25 million upfront licensing payment received from Recordati in the second quarter of 2025 rather than a deterioration in underlying commercial demand. The company highlighted continued progress under its fully partnered international commercialization strategy. Across its global partner network, in-market demand for VASCEPA/VAZKEPA increased 59% year over year, while European in-market demand rose 69%. In China, year-to-date in-market volume increased 90% compared with the same period last year. Amarin also reported significant cost reductions. Operating expenses declined 59% year over year to $27.0 million, while expenses excluding restructuring charges fell 38%, reflecting completion of the company’s previously announced $70 million annual cost savings initiative. The balance sheet continued to strengthen. Cash increased to $314.6 million from $302.6 million at the end of 2025, inventories declined substantially, and the company remained debt free. The results illustrate the financial impact of Amarin’s transition from directly commercializing VAZKEPA in Europe to a partnership-based model. While reported revenue declined because last year’s results included a one-time licensing payment, management emphasized that underlying patient demand continues to expand across partner markets. The completed restructuring has materially lowered Amarin’s operating cost base, improving cash generation and reducing the revenue required to support profitability. The company generated positive cash flow for the third consecutive quarter and expects its cash balance to grow further by year-end, suggesting improved financial flexibility. Amarin also maintained its competitive position in the U.S. despite ongoing generic competition. Although pricing pressure continued to weigh on U.S. product revenue, branded VASCEPA prescriptions increased and the company’s share of the U.S. icosapent ethyl market rose from 43% to 48%. Looking ahead, management continues to work with its financial advisor, Barclays, to evaluate additional opportunities to enhance shareholder value while supporting further international expansion through its commercial partners. Investors will likely monitor: Continued growth in VASCEPA and VAZKEPA demand across Amarin’s international partner network. Commercial launches in additional markets, including Singapore and South Korea. Progress in pricing, reimbursement, and market access across Recordati’s European territory. Whether positive cash flow and cash balances continue to improve through the remainder of 2026. Updates regarding strategic initiatives as the company continues working with Barclays. Amarin Corporation stock price

This article first appeared on GuruFocus. Release Date: July 29, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Amarin Corp PLC (NASDAQ:AMRN) has successfully implemented a dual commercial strategy, combining U.S. business execution with an international commercial platform, resulting in a scalable business model. VASCEPA is commercially available in 22 countries, with significant growth in international markets, particularly in Europe under the Recordati partnership. The company has completed restructuring activities, resulting in a significantly lower cost base and enhanced ability to execute long-term growth strategies. Amarin Corp PLC (NASDAQ:AMRN) reported positive cash flow for the third consecutive quarter, improving its cash position by $12 million from year-end 2025. The U.S. business remains profitable despite ongoing generic pressure, with VASCEPA retaining a leading position in the icosapent ethyl market. Total net revenue in Q2 2026 was $42.2 million, a decrease from $72.7 million in the same quarter last year, partly due to a $25 million upfront payment in 2025. U.S. product revenue declined to $32.2 million from $36.5 million in Q2 2025, driven by ongoing pricing pressure in the competitive generic market. European product revenue was $5.4 million, down from $6.6 million in Q2 2025, reflecting the transition to the Recordati partnership. Cost of goods sold in Q2 2026 rose by 22% to $27.2 million, primarily due to increased product volumes associated with regaining an exclusive PBM relationship in the U.S. The company reported an operating loss of $12 million in Q2 2026, although this was an improvement from a $16 million loss in the same period last year. Warning! GuruFocus has detected 3 Warning Signs with AMRN. Is AMRN fairly valued? Test your thesis with our free DCF calculator. Q: Can you provide an update on the reimbursement landscape in Europe, particularly in major markets? A: Aaron Berg, President and CEO, explained that reimbursement varies by country. Recordati is commercializing VASCEPA in the UK, Spain, Portugal, and Italy, with ongoing efforts to improve regional reimbursement. They are exploring additional countries, including France, though it is a lengthy process. Recordati's established presence in Italy is promising for future growth. Q: The cost of goods sold (COGS) was higher than expected. Is this a sustainable rate going forward? A: Pete Fishman, CFO, noted that COGS is calculated using a weighted average cost of inventory, primarily driven by API volumes. The increase from Q2 2025 to Q2 2026 was due to regaining a PBM exclusive. The variance should level off, and they have renegotiated supply agreements to manage costs effectively. Q: Are you seeing any revenues from Recordati, and what should we expect in terms of revenue ramp-up? A: Aaron Berg highlighted that in-market demand for Recordati in Europe has been strong, with a 69% increase. Pete Fishman added that licensing revenue includes royalty revenue, with $1.4 million from Recordati in Q2 2026, showing growth from Q1 2026. They are encouraged by the early momentum. Q: How is the international growth strategy progressing, particularly in Europe and other regions? A: Aaron Berg emphasized the promising international sales trajectory, with VASCEPA available in 22 countries. Recordati's partnership covers 59 countries in Europe, with significant growth in in-market demand. They are also advancing regulatory submissions in Asia, with recent approvals in Singapore and South Korea. Q: What are the financial highlights for Q2 2026? A: Pete Fishman reported total net revenue of $42.2 million, with product revenue at $39.1 million. U.S. product revenue declined due to pricing pressure but remained profitable. European revenue increased by 11% from Q1 2026. Operating expenses decreased by 59%, and the company generated $7 million in positive cash flow. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Amarin Corporation AMRN recorded adjusted earnings of 4 cents per share for the second quarter of 2026, down 95.4% year over year. The metric surpassed the Zacks Consensus Estimate of a loss of 9 cents. Adjusted earnings per share excluded stock-based compensation expense, restructuring expense and litigation-related charges. Total revenues in the quarter were $42.2 million, missing the Zacks Consensus Estimate of $46 million. Revenues decreased 42% from the year-ago quarter’s level. In the year-ago period, the company received an upfront payment of $25 million from Italy-based Recordati to commercialize Vazkepa across Europe. Year to date, Amarin's shares have seen no change, compared with the industry’s 4.5% growth. Image Source: Zacks Investment Research Amarin’s top line comprises product revenues from its sole marketed drug, Vascepa (icosapent ethyl), along with licensing and royalty revenues. The drug is approved as an adjunct to diet for the treatment of severe hypertriglyceridemia and to reduce cardiovascular risk in patients with persistently elevated triglycerides on statin therapy for LDL-C. Net product revenues from Vascepa in the second quarter were $39.1 million, down 16% year over year. This metric missed the Zacks Consensus Estimate of $43.1 million and our model estimates of $43.3 million. U.S. product revenues from Vascepa declined 12% year over year and 9.5% sequentially to $32.2 million. The decrease was primarily due to ongoing generic erosion, which continued to pressure net pricing. Product revenues from Vazkepa (Vascepa’s brand name in Europe) in the European market totaled $5.4 million, decreasing 17% from the year-ago quarter. This reflected the company’s transition to a fully partnered model with Recordati in the European market. However, Vazkepa sales increased 10.2% sequentially. Revenues in the Rest of the World were $1.4 million compared with $3.5 million in the year-ago quarter. The decline primarily reflected normal fluctuations in partner purchasing patterns and the timing of shipments across multiple international markets. However, Amarin expects combined in-market demand across its global partner markets to continue growing. Licensing and royalty revenues totaled $3.1 million, declining 88% year over year. Selling, general and administrative expenses (excluding stock-based compensation expense) declined 42.5% year over year to $20.6 million. Research and development expenses (excluding stock-based compensation expense) totaled $4.3 million, roughly consistent with the prior-year quarter. Amarin ended the quarter with cash and investments of $314.6 million compared with $307.8 million as of March 31, 2026, and remained debt free. Amarin continued to execute on its strategic transformation during the second quarter of 2026 following its exclusive long-term licensing and supply agreement with Recordati, signed in June 2025, to commercialize Vazkepa across 59 European-focused markets. The partnership has enabled the company to significantly lower its operating cost base while expanding Vazkepa's commercial footprint in Europe. As of June 30, 2026, the product was commercially available in 22 countries, including 11 European markets. In the United States, Amarin strengthened its leadership in the branded icosapent ethyl market, increasing its market share to 48% from 43% a year earlier, while branded Vascepa prescriptions grew 14% year over year. The company expects U.S. prescription volumes to remain stable throughout fiscal 2026. AMRN completed its previously announced $70 million annual cost-savings initiative this quarter. Management expects improved cost efficiency and sustained positive cash flow in 2026. Amarin Corporation PLC price-consensus-eps-surprise-chart | Amarin Corporation PLC Quote Amarin currently sports a Zacks Rank #1 (Strong Buy). Some other top-ranked stocks in the biotech sector are Harmony Biosciences HRMY, Liquidia Corporation LQDA and Neurocrine Biosciences NBIX. While HRMY and LQDA sport a Zacks Rank #1 each at present, NBIX carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Over the past 90 days, earnings per share estimates for Harmony Biosciences have decreased from $3.34 to $3.30 for 2026. Over the same period, estimates for earnings per share increased from $3.79 to $3.87 for 2027. HRMY shares have lost 4.4% year to date. Harmony Biosciences missed on earnings in each of the trailing four quarters, delivering an average negative surprise of 25.16%. Over the past 90 days, estimates for Liquidia’s 2026 earnings per share have increased to $3.02 from $1.50. Over the same period, EPS estimates for 2027 have risen to $5.31 from $2.91. LQDA shares have surged 151.7% year to date. Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%. Over the past 90 days, estimates for Neurocrine Biosciences’ 2026 earnings per share have risen from $8.00 to $9.09. Over the same period, EPS estimates for 2027 have increased from $9.48 to $10.81. NBIX shares have gained 28.9% year to date. Neurocrine Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 9.08%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amarin Corporation PLC (AMRN) : Free Stock Analysis Report Neurocrine Biosciences, Inc. (NBIX) : Free Stock Analysis Report Liquidia Corporation (LQDA) : Free Stock Analysis Report Harmony Biosciences Holdings, Inc. (HRMY) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Interested in Amarin Corporation PLC? Here are five stocks we like better. International demand strengthened: Global in-market VASCEPA demand rose 59% year over year, while European demand increased 69% in the second quarter. The product was commercially available in 22 countries, with Recordati leading its European rollout. U.S. sales faced pricing pressure: VASCEPA’s U.S. market share improved to 48% and branded prescriptions rose 14%, but U.S. product revenue declined to $32.2 million because of generic competition and lower pricing. Amarin’s financial position improved: Operating expenses fell 59% to $27 million, cash and investments increased to $314.6 million, and operating cash flow was positive for the third consecutive quarter. Management expects positive cash flow for full-year 2026. 3 Biotech Stocks Gaining Momentum Amarin (NASDAQ:AMRN) said its second-quarter results reflected progress in its dual commercial strategy, which combines a company-managed U.S. business with partnered commercialization internationally. Management highlighted growing demand for VASCEPA in Europe, cost reductions from a completed restructuring program and a third consecutive quarter of positive operating cash flow. President and Chief Executive Officer Aaron Berg described the quarter as an “inflection point” occurring one year after the company adopted its current commercial model. He said the restructuring has been completed, lowering the company’s cost base and providing what he called a clearer path toward sustainable growth and profitability. → This Tiny AI Supplier Could Be More Important Than the Chipmakers Are Ocugen or Amarin Good Penny Stocks to Buy? As of June 30, VASCEPA was commercially available in 22 countries. Amarin’s partner network includes Recordati in 59 European countries, as well as six commercial partnerships covering markets including Canada, China, Israel, the Middle East, Asia, Australia and New Zealand. Amarin reported that cumulative year-over-year in-market VASCEPA demand across its global partner network increased 59% as of June 30. In Europe, where Recordati is leading commercialization, in-market demand rose 69% in the second quarter from the prior-year period. → Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There? Does Amarin Deserve a Spot in Your Portfolio after Earnings ? VASCEPA is commercialized in 11 European countries, including a recent launch in Romania. Berg said Spain and the United Kingdom are leading early adoption, while Italy has also launched with commercial support from Recordati. He said the partner has positioned VAZKEPA as a priority cardiovascular brand and is supporting it with field representatives, medical science liaisons and marketing investment. During the question-and-answer session, Berg said reimbursement is in place in the United Kingdom, Spain and Portugal, while Italy is beginning its commercial rollout. He said Recordati is continuing to pursue pricing, reimbursement and market-access opportunities in other countries and identified France as a market Amarin would like to enter eventually, though he provided no timing update. → Innovative ETF Strategies That Are Paying Off This Summer Chief Financial Officer Peter Fishman said European product revenue totaled $5.4 million in the second quarter, consisting entirely of supply shipments to Recordati. That was below $6.6 million in the year-earlier quarter under Amarin’s prior direct-sales model, but was up 11% from the first quarter of 2026 and 140% from the fourth quarter of 2025. Licensing revenue included $1.4 million in royalty revenue during the quarter, Fishman said, with a portion related to Recordati. He said the company was encouraged by the early commercial momentum but did not provide revenue guidance. In the United States, Amarin said VASCEPA retained a 48% share of the icosapent ethyl market as of June 30, compared with 43% a year earlier. The overall U.S. icosapent ethyl market grew 3% year over year during the second quarter, according to third-party data cited by management. Branded VASCEPA prescriptions increased 14% from a year earlier despite generic competition and pricing pressure. Berg said Amarin expects U.S. volumes to remain stable through the end of 2026 and expects to maintain exclusivity arrangements with key payers through year-end. U.S. product revenue declined to $32.2 million from $36.5 million in the prior-year quarter. Fishman attributed the decline to ongoing pricing pressure in the generic market, partially offset by higher product volume. He said the U.S. business remains profitable and cash-generative. Total net revenue was $42.2 million, compared with $72.7 million in the second quarter of 2025. The prior-year figure included a $25 million upfront payment tied to the start of the Recordati transaction. Product revenue declined to $39.1 million from $46.6 million. Rest-of-world revenue was $1.4 million, down from $3.5 million a year earlier, which Fishman said reflected normal variation across developing markets. Cost of goods sold increased 22% to $27.2 million, primarily because of increased product volumes associated with regaining an exclusive pharmacy benefit manager relationship in the U.S. beginning in the third quarter of 2025. Fishman said the year-over-year comparison should begin to level off in future periods as the company moves beyond the impact of that volume increase. Total operating expenses fell 59%, or $39.3 million, to $27 million. Excluding a $22.8 million restructuring charge recorded in the second quarter of 2025, operating expenses declined 38% from the prior-year period. Selling, general and administrative expense declined 43% to $22.2 million. The company’s operating loss narrowed to $12 million from $16 million a year earlier. Amarin ended the quarter with $314.6 million in cash and investments, up from $303 million at the end of 2025, with no debt and working capital of $439 million. Operating cash flow was positive $7 million, marking the third consecutive quarter of positive cash flow. Management said it expects positive cash flow for full-year 2026. Inventory declined by $19.5 million from the end of the first quarter and by $31.8 million from year-end 2025, reflecting what Fishman described as disciplined purchasing and inventory management. President of Research and Development and Chief Scientific Officer Steven Ketchum said Amarin continues to support global commercialization through medical affairs, regulatory, technical operations and research activities. The company cited a post-hoc analysis from the REDUCE-IT placebo arm presented at the European Atherosclerosis Society Congress in May, which found that risk-weighted apolipoprotein B more effectively identified statin-treated patients with elevated triglycerides who remained at increased residual cardiovascular risk than traditional lipid biomarkers. Ketchum also said high-dose icosapent ethyl has been recommended for appropriate high-risk patients in the 2026 ACC/AHA Multi-Society Dyslipidemia Guideline and the ACC/AHA Multi-Society Cardiovascular Kidney Metabolic Syndrome Guideline. Amarin plans to support partner CSL Seqirus at a cardiovascular meeting in Australia and will participate in the European Society of Cardiology Congress in Munich, where it has five scientific abstracts accepted. Berg said Amarin is also working with financial adviser Barclays to evaluate additional opportunities to enhance shareholder value. Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin's primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies. The company's flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Amarin Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for July 2026.

Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA’s U.S. Market Share, an Improved OPEX Profile, and Positive Cash Flow Generation DUBLIN, Ireland and BRIDGEWATER, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the second quarter ended June 30, 2026 (Q2 2026) and highlighted positive outlooks associated with the one-year anniversary of its fully partnered international commercial strategy. In June 2025, Amarin entered into an exclusive long-term license and supply agreement with Recordati S.p.A. (“Recordati”) to commercialize VASCEPA®/VAZKEPA® (icosapent ethyl or IPE) across 59 countries focused in Europe. This transformational agreement enabled Amarin to significantly reduce its operating expenses while simultaneously expanding VAZKEPA’s presence in one of the world's largest cardiovascular pharmaceutical markets, where cardiovascular disease affects an estimated 62 million people and carries an annual economic burden of approximately €282 billion across the European Union.i While commercialization remains in the early stages, Recordati has made progress advancing pricing, reimbursement, market access and adoption across the licensed territory. “The strategic actions we have taken are driving stronger results and a path to sustained growth and profitability,” said Aaron Berg, President and Chief Executive Officer. “Amarin’s results for Q2 2026 demonstrated a positive early international sales trajectory as in-market demand increased 59% year over year across our global partner network. Operating expenses, excluding restructuring charges, declined by $16.6 million, or 38% compared to Q2 2025, in line with the previously announced $70 million annual cost savings initiative that we have now completed. We also maintained our leading U.S. IPE sales presence for VASCEPA. We are confident in the significant opportunities that lie ahead to improve patient outcomes, and continue to work closely with Barclays, our exclusive financial advisor, to explore additional potential pathways to further enhance shareholder value.” Select Operational Highlights and Outlook Across our global partner network, in-market demand for VASCEPA/VAZKEPA rose by 59% in Q2 2026 compared to Q2 2025, including 90% year-to-date growth in in-market volume in China versus the same period last year. In-market demand in Europe for VAZKEPA rose by 69% in Q2 2026 from Q2 2025. As of June 30, 2026, VASCEPA / VAZKEPA was commercially available in 22 countries across the globe. As of June 30, 2026, VAZKEPA is commercialized in 11 countries in Europe, with pricing, reimbursement, market access and adoption continuing to build across additional countries within Recordati’s licensed territory. The Company continues to work closely with our partners to advance regulatory submissions and support partners' needs through various stages of review and market launch preparations. Momentum remains strong across Europe and Asia, with Singapore and South Korea progressing toward anticipated near-term commercialization. The Company’s share of the U.S. IPE market increased to 48% in Q2 2026 compared to 43% in Q2 2025. VASCEPA branded prescriptions rose by 14% from Q2 2025. The Company expects that U.S. volumes will remain consistent throughout FY 2026. Select Financial Highlights and Outlook Operating expenses declined by $39.3 million, or 59% compared to Q2 2025. Excluding restructuring charges incurred in Q2 2025, operating expenses declined by $16.6 million, or 38%, in line with the previously announced and now completed $70 million annual cost savings initiative. Inventories as of June 30, 2026 declined by $19.5 million from March 31, 2026 and by $31.8 million from December 31, 2025. Cash as of June 30, 2026 was $314.6 million, compared to $302.6 million at December 31, 2025. The Company expects cash to grow by approximately 10% as of December 31, 2026 compared to December 31, 2025. The Company remained debt free as of June 30, 2026. Financial Highlights Peter Fishman, Amarin’s Chief Financial Officer, said, “We have established a materially lower operating expense baseline to support our global sales initiatives and position the Company to generate revenues more profitably than under our former model. We also generated positive cash flow for the third consecutive quarter, improved our cash position and maintained a disciplined, data-driven approach to inventory management that optimizes working capital while protecting product access.” Financial PerformanceComparisons to comparable 2025 periods, unless otherwise stated Revenues Total Net Revenue: Declined to $42.2 million, with the primary variance being a $25 million up front payment associated with the commencement of the Recordati agreement in Q2 2025; there was no such payment in Q2 2026. A modest decline in U.S. sales of VASCEPA was driven by continued generic competition in the IPE market and the resulting pressure on net pricing, partially offset by increased demand for branded VASCEPA. A slight decline in European revenue was attributable to moving to a partnered sales model beginning in the second half of 2025. Quarter-to-quarter European sales comparisons that reflect the partnership model with Recordati will commence in Q3 2026. While there was continued growth in Rest-of-World in-market demand, revenue in Q2 2026 was $1.4 million, down from $3.5 million in last year’s second quarter and reflective of normal variability in partner purchasing patterns and the timing of shipments across multiple geographies. The Company expects combined in-market demand across all its global partner markets to continue to grow. Lower licensing and royalty revenue in Q2 2026 reflected the above referenced Recordati payment received in last year’s second quarter, partially offset by royalties from the Recordati agreement in the current quarter. Operating ExpensesComparisons to comparable 2025 periods, unless otherwise stated COGS: Increased $4.8 million, or 22%, reflecting increased product volumes on which revenue was recognized during the period. SG&A: Decreased 43% to $22.2 million, reflecting a reduction in costs associated with the Global Restructuring Plan. R&D: Consistent with the prior year period. Restructuring: The Company’s Global Restructuring associated with the execution of the Recordati Licensing Agreement is now complete. Q2 2026 charges associated with this plan were immaterial. Second Quarter 2026 Earnings Conference Call and Webcast Information Amarin will host a conference call on July 29, 2026, at 8:00 a.m. ET to discuss this information. The conference call can be accessed on the investor relations section of the Company's website at www.amarincorp.com, or via telephone by dialing 888-506-0062 within the United States, 973-528-0011 from outside the United States, and referencing conference ID 444188. A replay of the webcast will be made available until January 29, 2027. To listen to a replay of the call, dial 877-481-4010 from within the United States and 919-882-2331 from outside of the United States, and reference conference ID 54179. A replay of the call will also be available through the Company's website shortly after the call. About Amarin Amarin is a global pharmaceutical company committed to reducing the cardiovascular disease (CVD) burden for patients and communities and to advancing the science of cardiovascular care around the world. We own and support a global branded product approved by multiple regulatory authorities based on a track record of proven efficacy and safety and backed by robust clinical trial evidence. Our commercialization model includes a direct sales approach in the U.S. and an indirect distribution strategy internationally, through a syndicate of reputable and well-established partners with significant geographic expertise, covering close to 100 markets worldwide. Our success is driven by a dedicated, talented, and highly skilled team of experts passionate about the fight against the world’s leading cause of death, CVD. About VASCEPA®/VAZKEPA® (icosapent ethyl) Capsules VASCEPA (icosapent ethyl) capsules are the first prescription treatment approved by the U.S. Food and Drug Administration (FDA) comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA was launched in the United States in January 2020 as the first drug approved by the U.S. FDA for treatment of the studied high-risk patients with persistent cardiovascular risk despite being on statin therapy. VASCEPA was initially launched in the United States in 2013 based on the drug’s initial FDA approved indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed more than thirty-one million times. VASCEPA is covered by most major medical insurance plans. In addition to the United States, VASCEPA is approved and sold in Canada, China, Australia, Lebanon, the United Arab Emirates, Saudi Arabia, Qatar, Bahrain, and Kuwait. In Europe, in March 2021 marketing authorization was granted to icosapent ethyl in the European Union for the reduction of risk of cardiovascular events in patients at high cardiovascular risk, under the brand name VAZKEPA. In April 2021 marketing authorization for VAZKEPA was granted in the United Kingdom (applying to England, Scotland, Wales, and Northern Ireland). VAZKEPA is currently approved and sold in Europe in Sweden, Finland, England/Wales, Spain, Netherlands, Scotland, Greece, Portugal, Italy, Slovenia, Romania, Denmark and Austria. United States Indications and Limitation of Use VASCEPA is indicated: As an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease or diabetes mellitus and two or more additional risk factors for cardiovascular disease. As an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. Important Safety Information VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components. VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter. It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur. VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin. Common adverse reactions in the cardiovascular outcomes trial (incidence ≥3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%), and atrial fibrillation (5% vs 4%). Common adverse reactions in the hypertriglyceridemia trials (incidence >1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%). Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088. Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding. FULL U.S. FDA-APPROVED VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM Europe For further information about the Summary of Product Characteristics (SmPC) for VAZKEPA® in Europe, please visit: https://www.ema.europa.eu/en/documents/product-information/vazkepa-epar-product-information_en.pdf Globally, prescribing information varies; refer to the individual country product label for complete information. Use of Non-GAAP Adjusted Financial Information Included in this press release are non-GAAP adjusted financial information as defined by U.S. Securities and Exchange Commission Regulation G. The GAAP financial measure is most directly comparable to each non-GAAP adjusted financial measure used or discussed, and a reconciliation of the differences between each non-GAAP adjusted financial measure and the comparable GAAP financial measure, is included in this press release after the condensed consolidated financial statements. Non-GAAP adjusted net (loss) income was derived by taking GAAP net loss and adjusting it for non-cash stock-based compensation expense, restructuring expense and other one-time expenses. Management uses these non-GAAP adjusted financial measures for internal reporting and forecasting purposes, when publicly providing its business outlook, to evaluate the company’s performance and to evaluate and compensate the company’s executives. The company has provided these non-GAAP financial measures in addition to GAAP financial results because it believes that these non-GAAP adjusted financial measures provide investors with a better understanding of the company’s historical results from its core business operations. While management believes that these non-GAAP adjusted financial measures provide useful supplemental information to investors regarding the underlying performance of the company’s business operations, investors are reminded to consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. Non-GAAP measures have limitations in that they do not reflect all the amounts associated with the company’s results of operations as determined in accordance with GAAP. In addition, it should be noted that these non-GAAP financial measures may be different from non-GAAP measures used by other companies, and management may utilize other measures to illustrate performance in the future. Forward-Looking Statements This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including beliefs about Amarin’s outlook for achievements in 2026 and beyond; Amarin’s overall efforts to expand access and reimbursement to VASCEPA/VAZKEPA across global markets; expectations regarding potential market dynamics, payer behavior, and the competitive landscape; and the overall potential and future success of VASCEPA/VAZKEPA and Amarin that are based on the beliefs and assumptions and information currently available to Amarin. All statements other than statements of historical fact contained in this press release are forward-looking statements. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin’s filings with the U.S. Securities and Exchange Commission, including Amarin’s annual report on Form 10-K for the fiscal year ended 2025 and subsequent quarterly reports on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin Contact Information Media Inquiries:Amarin Corporation [email protected] Investor Inquiries: Devin Sullivan & Conor RodriguezThe Equity Group on Behalf of [email protected] or [email protected]@amarincorp.com i OECD (2025), The State of Cardiovascular Health in the European Union, OECD Publishing, Paris, https://doi.org/10.1787/ea7a15f4-en.